

Art Unit: 1625

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Jennifer Che on May 17, 2007.

2. The application has been amended as follows:

LC
7/09/07
A. At claim 63, the phrase "according to ^{one}any of claims 54-62 has been amended to read in favor of:

-- according to any one of claims 54-61--.

B. New claim 80 has been added as follows:

80
80. (New) The compound according to claim 62, wherein R² is ethyl:

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

3. Based upon the telephonic interview, of record, dated March 30, 2007, the relevant section of the M.P.E.P. is §608.01(n).

4. The rejection under 35 U.S.C. §103 is withdrawn based upon the obligation of assignment to Vertex Pharmaceuticals. In order to complete the record, the assignment of 10/609,147, which corresponds to WO/2004/002961, is listed on the PTO-892.

5. Claim 63 has been amended to change the dependency of the claim. New claim 90 has been added to include the dependency to claim 62.